Showing results (211-220 of 283) with videos related to

Sort By:
Pageof 29
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|May 24, 2012
Sentinel node status predicts survival in thick melanomas: the Oxford perspectiveM G Rughani, M C Swan, T S Adams, et al.
British Journal of Cancer|December 1, 1987
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerM H Bronchud, J H Scarffe, N Thatcher, et al.
Ultrasonics|March 30, 2004
High-intensity focused ultrasound for the treatment of liver tumoursJ E Kennedy, F Wu, G R ter Haar, et al.
International Journal of Cancer|September 30, 1992
Prevalence of the Rhesus-negative phenotype in Caucasian patients with small-cell lung cancer (SCLC)T Cerny, M F Fey, R Oppliger, et al.
Lung Cancer (Amsterdam, Netherlands)|July 23, 2003
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancerJ P Braybrooke, M Ranson, C Manegold, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|January 1, 1995
Increasing and planned dose intensity of doxorubicin, cyclophosphamide and etoposide (ACE) by adding recombinant human methionyl granulocyte colony-stimulating factor (G-CSF; filgrastim) in the treatment of small cell lung cancer (SCLC). Medical Research Council Lung Cancer Working PartyN Thatcher, P I Clark, D B Smith, et al.
British Journal of Cancer|August 1, 1993
A phase I study of intravenous bryostatin 1 in patients with advanced cancerJ Prendiville, D Crowther, N Thatcher, et al.
British Journal of Cancer|July 16, 2009
Societal preference values for advanced melanoma health states in the United Kingdom and AustraliaK M Beusterien, S M Szabo, S Kotapati, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II studyH von der Maase, P Geertsen, N Thatcher, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2016
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerL Paz-Ares, M A Socinski, J Shahidi, et al.
Pageof 29